Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine.

BACKGROUND Quinidine is used to treat atrial fibrillation and ventricular arrhythmias. However, at low concentrations, it can induce torsade de pointes (TdP). OBJECTIVE The purpose of this study was to examine the role of late sodium current (I(Na)) as a modulator of the arrhythmogenicity of quinidine in female rabbit isolated hearts and cardiomyocytes. METHODS Epicardial and endocardial monophasic action potentials (MAPs), ECG signals, and ion channel currents were measured. The sea anemone toxin ATX-II was used to increase late I(Na). RESULTS Quinidine had concentration-dependent and often biphasic effects on measures of arrhythmogenicity. Quinidine increased the duration of epicardial MAP (MAPD(90)), QT interval, transmural dispersion of repolarization (TDR), and ventricular effective refractory period. Beat-to-beat variability of MAPD(90) (BVR), the interval from peak to end of the T wave (Tpeak-Tend) and index of Tpeak-Tend/QT interval were greater at 0.1 to 3 micromol/L than at 10-30 micromol/L quinidine. In the presence of 1 nmol/L ATX-II, quinidine caused significantly greater concentration-dependent and biphasic changes of Tpeak-Tend, TDR, BVR, and index of Tpeak-Tend/QT interval. Quinidine (1 micromol/L) induced TdP in 2 and 13 of 14 hearts in the absence and presence of ATX-II, respectively. Increases of BVR, index of Tpeak-Tend/QT interval, and Tpeak-Tend were associated with quinidine-induced TdP. Quinidine inhibited I(Kr), peak I(Na), and late I(Na) with IC(50)s of 4.5 +/- 0.3 micromol/L, 11.0 +/- 0.7 micromol/L, and 12.0 +/- 0.7 micromol/L. CONCLUSION Quinidine had biphasic proarrhythmic effects in the presence of ATX-II, suggesting that late I(Na) is a modulator of the arrhythmogenicity of quinidine. Enhancement of late I(Na) increased proarrhythmia caused by low but not high concentrations of quinidine.

[1]  D. Roden,et al.  Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. , 1986, American heart journal.

[2]  H. Mabuchi,et al.  T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. , 2003, Clinical science.

[3]  E. Aliot,et al.  The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. , 1988, Progress in cardiovascular diseases.

[4]  J. Reiffel Inpatient versus outpatient antiarrhythmic drug initiation: safety and cost-effectiveness issues. , 2000, Current opinion in cardiology.

[5]  J. Shryock,et al.  An Increase in Late Sodium Current Potentiates the Proarrhythmic Activities of Low-Risk QT-Prolonging Drugs in Female Rabbit Hearts , 2006, Journal of Pharmacology and Experimental Therapeutics.

[6]  P. Kowey,et al.  Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. , 1997, Circulation.

[7]  F. Cappuccio,et al.  Risk of Cardiac Arrhythmia Variant of SCN 5 A Sodium Channel Implicated in , 2007 .

[8]  E. Kaufman Quinidine in Short QT Syndrome: An Old Drug for a New Disease , 2007, Journal of cardiovascular electrophysiology.

[9]  Milan Stengl,et al.  Increased Short-Term Variability of Repolarization Predicts d-Sotalol–Induced Torsades de Pointes in Dogs , 2004, Circulation.

[10]  G. Breithardt,et al.  Reduction of Dispersion of Repolarization and Prolongation of Postrepolarization Refractoriness Explain the Antiarrhythmic Effects of Quinidine in a Model of Short QT Syndrome , 2007, Journal of cardiovascular electrophysiology.

[11]  N. Benowitz,et al.  Poisoning Due to Class IA Antiarrhythmic Drugs , 1990 .

[12]  Antoine Leenhardt,et al.  Hydroquinidine therapy in Brugada syndrome. , 2004, Journal of the American College of Cardiology.

[13]  J. Ruskin,et al.  Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. , 2008, Cardiovascular research.

[14]  L. Toivonen,et al.  Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. , 2007, Heart rhythm.

[15]  J. Salata,et al.  Effects of Quinidine on Action Potentials and Ionic Currents in Isolated Canine Ventricular Myocytes , 1988, Circulation research.

[16]  J. M. Di Diego,et al.  Cisapride-Induced Transmural Dispersion of Repolarization and Torsade de Pointes in the Canine Left Ventricular Wedge Preparation During Epicardial Stimulation , 2003, Circulation.

[17]  M. Pepe The Statistical Evaluation of Medical Tests for Classification and Prediction , 2003 .

[18]  J. Shryock,et al.  Use of preclinical assays to predict risk of drug-induced torsades de pointes. , 2005, Heart rhythm.

[19]  M. Sokolow Some quantitative aspects of treatment with quinidine. , 1956, Annals of internal medicine.

[20]  J. Papp,et al.  Comparison of the Effect of Class IA Antiarrhythmic Drugs on Transmembrane Potassium Currents in Rabbit Ventricular Myocytes , 2003, Journal of cardiovascular pharmacology and therapeutics.

[21]  P. C. Viswanathan,et al.  Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes , 2002, Circulation.

[22]  H. Tan,et al.  Electrophysiologic Mechanisms of the Long QT Interval Syndromes and Torsade de Pointes , 1995, Annals of Internal Medicine.

[23]  G. Naccarelli,et al.  Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. , 2003, The American journal of cardiology.

[24]  D. Roden,et al.  Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. , 1996, Circulation.

[25]  R. Lazzara Antiarrhythmic drugs and torsade de pointes. , 1993, European heart journal.

[26]  N. Benowitz,et al.  Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide. , 1990, Drug safety.

[27]  Charles Antzelevitch,et al.  Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. , 2008, Heart rhythm.

[28]  M. Cárdenas,et al.  Ionic Basis of Pharmacological Therapy in Brugada Syndrome , 2007, Journal of cardiovascular electrophysiology.

[29]  S. Swiryn,et al.  Torsade de pointes due to quinidine: observations in 31 patients. , 1984, American heart journal.